Piamprimab (AK105)

PreclinicalSmall molecule

HHenan Cancer Hospital

Piamprimab (AK105) is one of 50 small molecule programs targeting Soft Tissue Sarcoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Soft Tissue SarcomaActive, not recruiting

Soft Tissue SarcomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

258 competitors in Soft Tissue Sarcoma

#DrugCompanyPhaseTrials

Adriamycin

Pfizer

Phase 3

34 2

Votrient

Novartis

Phase 3

16 3

Ifex

BBaxter Healthcare Corporation

Phase 3

32 4

Gemzar

Johnson & Johnson

Phase 3

11 5

Yondelis

AApotex Inc.

Phase 3

17 6

Halaven

Eisai

Phase 3

3 7

Ellence

Pfizer

Phase 3

2 8

Neulasta

Amgen

Phase 3

2 9

Taxotere

AAvyxa

Phase 3

10 10

Cytoxan

BBaxter Healthcare Corporation

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Soft Tissue Sarcoma1 trial

Piamprilizumab (AK105) Combined With Radiotherapy for Neoadjuvant Treatment of Soft Tissue Sarcoma

Unknown status·HHenan Cancer Hospital·N/A·NCT05718778·31 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Piamprimab (AK105). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Piamprimab (AK105) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Piamprimab (AK105). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Henan Cancer Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: HHenan Cancer Hospital

Piamprimab (AK105)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Soft Tissue Sarcoma1 trial

References

Drug Info

Quick Facts

Related News